Patents - Paul F. Reid:
http://v3.espacenet.com/searchResults?DB=EPODOC&submitted=true&locale=en_EP&IN=Reid&AB=venom&ST=advanced&compact=false
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=REID%2C+PAUL+F&FIELD1=IN&co1=AND&TERM2=&FIELD2=&d=PG01
Ref:
http://www.receptopharm.com/about/management_team.php
United States Patent Application 20070190167
Kind Code A1
Reid; Paul F. ; et al. August 16, 2007
Use of cobratoxin as an analgesic
Abstract
A composition of matter for an analgesia and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to blocking of the action of acetylcholine at nicotinic acetylcholine receptors.
Inventors: Reid; Paul F.; (Plantation, FL) ; Qin; Zheng Hong; (Plantation, FL)
1. A method of treatment of pain in a host by administering a pharmaceutical composition of matter comprising a therapeutically effective amount of cobratoxin and a pharmaceutically acceptable carrier base for use in inhibiting or controlling pain.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070190167%22.PGNR.&OS=DN/20070190167&RS=DN/20070190167
http://v3.espacenet.com/searchResults?DB=EPODOC&submitted=true&locale=en_EP&IN=Reid&AB=venom&ST=advanced&compact=false
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=REID%2C+PAUL+F&FIELD1=IN&co1=AND&TERM2=&FIELD2=&d=PG01
Ref:
http://www.receptopharm.com/about/management_team.php
United States Patent Application 20070190167
Kind Code A1
Reid; Paul F. ; et al. August 16, 2007
Use of cobratoxin as an analgesic
Abstract
A composition of matter for an analgesia and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to blocking of the action of acetylcholine at nicotinic acetylcholine receptors.
Inventors: Reid; Paul F.; (Plantation, FL) ; Qin; Zheng Hong; (Plantation, FL)
1. A method of treatment of pain in a host by administering a pharmaceutical composition of matter comprising a therapeutically effective amount of cobratoxin and a pharmaceutically acceptable carrier base for use in inhibiting or controlling pain.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220070190167%22.PGNR.&OS=DN/20070190167&RS=DN/20070190167
Recent NPHC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/20/2026 08:51:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/06/2026 09:10:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/25/2026 06:38:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/11/2026 07:22:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/17/2026 07:11:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/02/2026 06:52:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/23/2025 06:15:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/17/2025 10:08:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/24/2025 06:48:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/28/2025 08:02:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/23/2025 05:43:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/16/2025 08:38:46 PM

